The most recent WHO diagnostic criteria for MPAL published in 2022 [5] now accounts for the intensity of the lineage-defining marker (e.g., MPO), requiring it to be at least 50% when compared to expression in the most similar population (e.g., neutrophils for myeloid lineage). Here, MPO is linked to mixed phenotype acute leukemia.